Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Vomiting 1Breast Neoplasms 1

Interventions

Letrozole 23Docetaxel 17Cyclophosphamide 13Zoledronic Acid 12Trastuzumab 12Anastrozole 12exemestane 11Tamoxifen 11Paclitaxel 11Capecitabine 10Fulvestrant 8Epirubicin 8pegfilgrastim 7Saline Solution 7Bupivacaine 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Sodium Chloride 6Filgrastim 6Carboplatin 6pegylated granulocyte colony-stimulating factor 5palbociclib 5Ropivacaine 5Dexmedetomidine 5Bevacizumab 5ribociclib 4eribulin 4Vinorelbine 4Tranexamic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × fosaprepitant × Breast × Clear all
NCT05841849 2023-05-03

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 4 Not yet recruiting
1,028 enrolled
Breast

Breast Neoplasms, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡